India plans to manufacture over 2 billion doses of COVID-19 vaccines by December
On Monday, England’s Prime Minister Boris Johnson is expected to announce a delay in the country’s reopening plan due to a rising concern about the COVID-19 Delta variant that originated in India. England was posed to remove all of the remaining restrictions on June 21, but as cases are on the rise, public health experts are warning that the new variant may pose a significant risk. The decision comes out of an abundance of caution, due to the Delta variant having been reported to be more transmissible than the strain that swept across the country over the winter.
In Thailand, delays in a mass inoculation effort continue amid one of the worst outbreaks of COVID-19 the country has seen since the start of the pandemic. Health officials had initially planned to have 70% of the population vaccinated by the end of the year, but a week after the program was supposed to begin, many people have had their appointments cancelled. As of Monday, only about 3% of Thailand has been fully vaccinated.
In Italy, the government recently announced that it was restricting the use of the AstraZeneca vaccine to only those people over the age of 60. The decision comes after an 18 year old passed away after receiving the shot in late May.
62.03 per 100
92.49 per 100
18.07 per 100
36.76 per 100
105.09 per 100
71.74 per 100
65.31 per 100
69.87 per 100
22.5 per 100
11.6 per 100
Data Table per Our World in Data (June 13, 2021, 12 AM EST)
In the United States, California will fully reopen its economy and take away most social distancing rules on Tuesday, as the state has now administered 40 million doses of COVID-19 vaccines.
102.25 per 100
83.54 per 100
106.00 per 100
91.80 per 100
103.64 per 100
96.15 per 100
87.73 per 100
108.32 per 100
90.51 per 100
102.81 per 100
Data Table per CDC COVID-19 Tracker (June 13, 2021, 6 AM EST)
For more information on COVID-19 vaccination research, distribution, and assessment, check out some of these recent Contagion stories:
Novavax COVID-19 Vaccine Provides 90% Efficacy, Will Submit for Regulation
Discussing Nanoparticle and Adenovirus Vaccine Platforms